Alumis Inc. (ALMS) Dividend History

Alumis Inc. (ALMS) is a biotechnology company focused on developing innovative therapies and solutions primarily within the healthcare and life sciences sectors. The company emphasizes advancing scientific research and technology to address unmet needs in medical treatments, often concentrating on areas such as antibody engineering and advanced therapeutics.

280 East Grand Avenue, South San Francisco, CA, 94080
Phone: 650-231-6625
Website: https://www.alumis.com

Dividend History

Alumis Inc. currently does not pay dividends

Company News

  • Alumis Misses Q2 Revenue as Costs Jump

    Alumis reported mixed Q2 2025 results, with missed revenue expectations and high operating expenses due to the ACELYRIN merger. The company completed patient enrollment in key clinical trials for envudeucitinib and maintains sufficient funding through 2027.

    The Motley Fool
  • Alumis Completes Merger with ACELYRIN

    Alumis Inc. has completed its merger with ACELYRIN, Inc. The merger strengthens Alumis' balance sheet and supports the advancement of its late-stage pipeline of targeted therapies for immune-mediated diseases.

    Benzinga
  • Alumis Stockholders Approve Merger with ACELYRIN

    Alumis Inc. and ACELYRIN, INC. announced that Alumis' stockholders voted to approve the pending merger between the two companies. The merger is expected to close in the second quarter of 2025, subject to customary closing conditions.

    GlobeNewswire Inc.
Page data last updated 08/19/2025 16:47:38 UTC